{
    "clinical_study": {
        "@rank": "136181", 
        "arm_group": {
            "arm_group_label": "desloratadine (5 mg or 10 mg)", 
            "arm_group_type": "Experimental", 
            "description": "Desloratadine, 5 mg, orally, once daily, one 5-mg tablet in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day up to 10 mg/day (two 5 mg tablets in the evening), if criteria for dose up-titration are met and there is insufficient anti-pruritic efficacy and no safety concern"
        }, 
        "brief_summary": {
            "textblock": "This is a efficacy and safety study of up to 12 weeks of desolatadine in Japanese\n      participants with eczema/dermatitis and dermal pruritus."
        }, 
        "brief_title": "An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Eczema", 
            "Dermatitis", 
            "Dermal Pruritus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Eczema", 
                "Pruritus"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic\n             dermatitis, nummular eczema, seborrheic dermatitis, asteatotic eczema,\n             neurodermatitis, etc. among eczema/dermatitis for which the observation of pruritus\n             is appropriate)\n\n          -  Dermal pruritus (generalized dermal pruritus, localized dermal pruritus)\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity to antihistamines or ingredients of a study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916980", 
            "org_study_id": "4117-202"
        }, 
        "intervention": {
            "arm_group_label": "desloratadine (5 mg or 10 mg)", 
            "description": "Desloratadine, 5 mg, orally, once daily, one 5-mg tablet in the evening for up to 12 weeks (Desloratadine, 10 mg/day, orally, once daily, two 5-mg tablets in the evening for up to 8 weeks)", 
            "intervention_name": "Desloratadine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Desloratadine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dermatitis", 
            "Dermatitis, Atopic", 
            "Skin Diseases", 
            "Skin Diseases, Genetic", 
            "Genetic Diseases, Inborn", 
            "Skin Diseases, Eczematous", 
            "Hypersensitivity, Immediate", 
            "Hypersensitivity", 
            "Immune System Diseases"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in pruritus/itch score (sum of daytime and nighttime scores) assessed by investigator at Week 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 2"
            }, 
            {
                "measure": "Percentage of participants who experienced at least one adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 weeks"
            }, 
            {
                "measure": "Percentage of participants who discontinued from study drug due to an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916980"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in pruritus/itch score (sum of daytime and nighttime scores) assessed by investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, Week 4, Week 6, Week 8, and Week 12"
            }, 
            {
                "measure": "Number of participants with improvement in the Global Improvement Rate assessed by investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, Week 2, Week 4, Week 6, Week 8, and Week 12"
            }, 
            {
                "measure": "Change from baseline in the degree of pruritus recorded by participants", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, Week 2, Week 4, Week 6, Week 8, and Week 12"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}